Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Zynga Slips To Loss In Q4 - Quick Facts

RELATED NEWS
Trade ZNGA now with 

Zynga Inc. (ZNGA: Quote) reported that its fourth-quarter net loss attributable to common stockholders was $435.01 million, compared to net income of $16.06 million in the same quarter last year. On per share basis, net loss for the quarter was $1.22 compared to net income of $0.05 for the fourth quarter of 2010.

The latest quarter results included $510 million of stock-based compensation expense for restricted stock units issued to employees that was previously unrecognized until triggered by initial public offering.

Non-GAAP earnings per share was $0.05 for the fourth quarter of 2011 compared to $0.09 for the fourth quarter of 2010.

Total Revenue was $311.24 million up from $195.76 million in the year ago quarter. Bookings were at a record level of $306.5 million for the fourth quarter of 2011, an increase of 26% compared to the fourth quarter of 2010 and an increase of 7% compared to the third quarter of 2011.

Looking ahead for fiscal 2012, non-GAAP earnings per share is projected to be in the range of $0.24 to $0.28. Bookings are projected to be in the range of $1.35 billion to $1.45 billion.

Click here to receive FREE breaking news email alerts for Zynga Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.